- ICH GCP
- Registro de ensayos clínicos de EE. UU.
- Ensayo clínico NCT03944850
Computerized Anxiety Sensitivity Treatment for Opioid Use Disorders (CAST-O)
3 de noviembre de 2020 actualizado por: Amanda M. Raines, Southeast Louisiana Veterans Health Care System
Evaluating the Utility of a Brief Computerized Anxiety Sensitivity Intervention for Opioid Use Disorders: A Pilot Investigation
The primary aim of the current project is to test the acceptability and feasibility of a computerized intervention, titled Computerized Anxiety Sensitivity Treatment (CAST), delivered to Veterans seeking treatment for an opioid use disorder.
The second aim of the study is to examine the utility of CAST by gathering data on symptom change.
The final aim of the current study is to test the effects of CAST on rates of attendance and retention in a substance use disorder treatment (SUDT) program.
Descripción general del estudio
Estado
Terminado
Condiciones
Intervención / Tratamiento
Descripción detallada
The pilot project will examine the effects of a brief, one-session computerized intervention delivered to Veterans seeking treatment for an opioid use disorder.
The opioid epidemic in the United States (US) is having a disproportionate impact on Veterans.
Indeed, Veterans are twice as likely to die from an accidental opioid overdose than members of the general population, even after accounting for gender and age distribution.
Although many individuals with an opioid addiction seek treatment, a large proportion drop out prematurely and/or relapse, highlighting the need to identify modifiable factors that may contribute to this process.
One variable that may be useful in understanding attrition in addiction treatment is anxiety sensitivity (AS).
AS is a well-established psychological risk factor reflecting the tendency to fear anxious arousal due to the belief that this arousal will have harmful physical, mental, and/or social consequences.
AS is elevated in opioid use populations and predicts treatment dropout among opioid users.
Importantly, research suggests that AS is highly malleable.
Despite this, to our knowledge no published research to date has systematically explored the utility of AS reduction protocols among opioid users.
The first aim of the current project is to test the acceptability and feasibility of a brief, one-session Computerized AS Treatment (CAST) delivered to Veterans seeking treatment for an opioid use disorder.
Because this is a pilot project and the study will likely be underpowered to detect treatment effects, we will not emphasize symptom reduction.
Nevertheless, a second aim of the current project is to examine the utility of CAST by gathering data on symptom change.
Finally, a third aim of the current project is to examine the effects of CAST on rates of attendance and retention in a substance use disorder treatment (SUDT) program.
Tipo de estudio
Intervencionista
Inscripción (Actual)
32
Fase
- No aplica
Contactos y Ubicaciones
Esta sección proporciona los datos de contacto de quienes realizan el estudio e información sobre dónde se lleva a cabo este estudio.
Ubicaciones de estudio
-
-
Louisiana
-
New Orleans, Louisiana, Estados Unidos, 70119
- Southeast Louisiana Veterans Health Care System
-
-
Criterios de participación
Los investigadores buscan personas que se ajusten a una determinada descripción, denominada criterio de elegibilidad. Algunos ejemplos de estos criterios son el estado de salud general de una persona o tratamientos previos.
Criterio de elegibilidad
Edades elegibles para estudiar
18 años y mayores (Adulto, Adulto Mayor)
Acepta Voluntarios Saludables
No
Géneros elegibles para el estudio
Todos
Descripción
Inclusion Criteria:
- Veterans must be diagnosed with an opioid use disorder
Exclusion Criteria:
- Less than 18 years of age
- Actively suicidal
- Actively psychotic
- Uncontrolled bipolar disorder (i.e., not stable on medications for at least one month)
Plan de estudios
Esta sección proporciona detalles del plan de estudio, incluido cómo está diseñado el estudio y qué mide el estudio.
¿Cómo está diseñado el estudio?
Detalles de diseño
- Propósito principal: Tratamiento
- Asignación: N / A
- Modelo Intervencionista: Asignación de un solo grupo
- Enmascaramiento: Ninguno (etiqueta abierta)
Armas e Intervenciones
Grupo de participantes/brazo |
Intervención / Tratamiento |
|---|---|
|
Experimental: Computerized Anxiety Sensitivity Treatment
CAST is a newly developed computerized intervention designed to closely model the educational and behavioral techniques that are commonly used in the treatment of anxiety and related conditions.The one time intervention takes approximately 45 minutes to complete.
|
CAST is a newly developed computerized intervention designed to closely model the educational and behavioral techniques that are commonly used in the treatment of anxiety and related conditions.
A psychoeducation component focuses on the nature of anxiety and its effects on the mind and body.
Veterans will be taught that physiological and psychological arousal is not dangerous, although they may have developed a conditioned fear of this arousal.
Interoceptive exposure (IE) exercises will also be introduced to as a way to reduce or eliminate the conditioned fear response.
|
¿Qué mide el estudio?
Medidas de resultado primarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
Intervention Acceptability Questionnaire (IAQ)
Periodo de tiempo: One week post-intervention
|
The IAQ is an 11-item self-report questionnaire designed to measure treatment satisfaction.
The IAQ includes nine items assessing acceptability (e.g., Do you think the information provided during the computerized intervention was helpful?
How likely are you to use the information and techniques you learned during the computerized intervention?), which are rated on a 4-point Likert-type scale (0 = no; 1 = somewhat; 2 = moderately; 3 = yes) and two free response items requesting suggestions for improving the treatment.
The IAQ will be administered at post-intervention to allow us to assess treatment acceptability.
|
One week post-intervention
|
Medidas de resultado secundarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
Alcohol Use Disorders Identification Test (AUDIT)
Periodo de tiempo: Baseline
|
The AUDIT is a 10-item self-report questionnaire designed by the World Health Organization to classify individuals with alcohol-related problems.
The AUDIT will be administered at baseline for descriptive purposes.
|
Baseline
|
|
Drug Use Disorders Identification Test (DUDIT)
Periodo de tiempo: Baseline
|
The DUDIT is an 11-item self-report questionnaire intended for use with the AUDIT as a way to classify individuals with drug-related problems.
The DUDIT will be administered at baseline for descriptive purposes
|
Baseline
|
|
PTSD Checklist for DSM-5 (PCL-5)
Periodo de tiempo: Baseline
|
The PCL-5 is a 20-item self-report questionnaire designed to assess DSM-5 symptoms of PTSD.
The PCL-5 will be administered at baseline for descriptive purposes.
|
Baseline
|
|
Anxiety Sensitivity Index-3 (ASI-3)
Periodo de tiempo: Baseline, One week post-intervention, and Four weeks post-intervention
|
The ASI-3 is an 18-item self-report questionnaire designed to measure fear of and concern about the negative effects of anxious arousal.
The ASI-3 will be administered at all timepoints to allow us to assess treatment-related changes in AS.
|
Baseline, One week post-intervention, and Four weeks post-intervention
|
|
Depression Anxiety Stress Scale (DASS)
Periodo de tiempo: Baseline, One week post-intervention, and Four weeks post-intervention
|
The DASS is a 21-item self-report questionnaire assessing depression, anxiety, and stress symptoms.
The DASS will be administered at all timepoints to allow us to assess treatment-related changes in depression, anxiety, and stress symptoms.
|
Baseline, One week post-intervention, and Four weeks post-intervention
|
|
Depression Symptom Inventory-Suicide Subscale (DSI-SS)
Periodo de tiempo: Baseline, One week post-intervention, and Four weeks post-intervention
|
The DSI-SS is a four-item self-report questionnaire designed to assess suicidal ideation, suicidal plans, control of suicidal thoughts, and suicidal impulses.
The DSI-SS will be administered at all timepoints to allow us to assess treatment-related changes in suicidality.
|
Baseline, One week post-intervention, and Four weeks post-intervention
|
|
Desires for Drug Questionnaire (DDQ)
Periodo de tiempo: Baseline, One week post-intervention, and Four weeks post-intervention
|
The DDQ is a 13-item self-report questionnaire designed to measure instant (i.e., present moment) cravings associated with opioid use.
The DDQ will be administered at all timepoints to allow us to assess treatment-related changes in cravings.
|
Baseline, One week post-intervention, and Four weeks post-intervention
|
|
Obsessive Compulsive Drug Use Scale (OCDUS)
Periodo de tiempo: Baseline, One week post-intervention, and Four weeks post-intervention
|
The OCDUS is a 12-item self-report questionnaire designed to assess heroin thoughts and interference, intention to use heroin and control of its consumption, and resistance against thoughts and decisions to use heroin.
The OCDUS will be administered at all timepoints to allow us to assess treatment related changes in thoughts and control over thoughts.
|
Baseline, One week post-intervention, and Four weeks post-intervention
|
|
Short Opiate Withdrawal Scale (SOWS)
Periodo de tiempo: Baseline, One week post-intervention, and Four weeks post-intervention
|
The SOWS is a 10-item self-report questionnaire designed to assess various symptoms of opiate withdrawal.
The SOWS will be administered at all timepoints to allow us to assess treatment-related changes in withdrawal symptoms.
|
Baseline, One week post-intervention, and Four weeks post-intervention
|
|
Work and Social Adjustment Scale (WSAS)
Periodo de tiempo: Baseline, One week post-intervention, and Four weeks post-intervention
|
The WSAS is a 5-item descriptive measure of subjective interference of psychiatric symptoms in various life domains (e.g., work, leisure, and family).
The WSAS will be administered at all timepoints to allow us to assess treatment-related changes in global life domains.
|
Baseline, One week post-intervention, and Four weeks post-intervention
|
Colaboradores e Investigadores
Aquí es donde encontrará personas y organizaciones involucradas en este estudio.
Patrocinador
Investigadores
- Investigador principal: Amanda M Raines, PhD, Southeast Louisiana Veterans Health Care System
Publicaciones y enlaces útiles
La persona responsable de ingresar información sobre el estudio proporciona voluntariamente estas publicaciones. Estos pueden ser sobre cualquier cosa relacionada con el estudio.
Publicaciones Generales
- Bohnert AS, Valenstein M, Bair MJ, Ganoczy D, McCarthy JF, Ilgen MA, Blow FC. Association between opioid prescribing patterns and opioid overdose-related deaths. JAMA. 2011 Apr 6;305(13):1315-21. doi: 10.1001/jama.2011.370.
- Keough ME, Schmidt NB. Refinement of a brief anxiety sensitivity reduction intervention. J Consult Clin Psychol. 2012 Oct;80(5):766-72. doi: 10.1037/a0027961. Epub 2012 Apr 2.
- Schmidt NB, Capron DW, Raines AM, Allan NP. Randomized clinical trial evaluating the efficacy of a brief intervention targeting anxiety sensitivity cognitive concerns. J Consult Clin Psychol. 2014 Dec;82(6):1023-33. doi: 10.1037/a0036651. Epub 2014 May 12.
- Schmidt NB, Eggleston AM, Woolaway-Bickel K, Fitzpatrick KK, Vasey MW, Richey JA. Anxiety Sensitivity Amelioration Training (ASAT): a longitudinal primary prevention program targeting cognitive vulnerability. J Anxiety Disord. 2007;21(3):302-19. doi: 10.1016/j.janxdis.2006.06.002. Epub 2006 Aug 4.
- Hearon BA, Calkins AW, Halperin DM, McHugh RK, Murray HW, Otto MW. Anxiety sensitivity and illicit sedative use among opiate-dependent women and men. Am J Drug Alcohol Abuse. 2011 Jan;37(1):43-7. doi: 10.3109/00952990.2010.535581. Epub 2010 Nov 19. Erratum In: Am J Drug Alcohol Abuse. 2011 Jan;37(1):47.
- Bohnert AS, Ilgen MA, Galea S, McCarthy JF, Blow FC. Accidental poisoning mortality among patients in the Department of Veterans Affairs Health System. Med Care. 2011 Apr;49(4):393-6. doi: 10.1097/MLR.0b013e318202aa27.
- Veilleux JC, Colvin PJ, Anderson J, York C, Heinz AJ. A review of opioid dependence treatment: pharmacological and psychosocial interventions to treat opioid addiction. Clin Psychol Rev. 2010 Mar;30(2):155-66. doi: 10.1016/j.cpr.2009.10.006. Epub 2009 Oct 30.
- Reiss, S. and R. McNally, Expectancy model of fear, in Theoretical Issues in Behavior Therapy, S. Reiss and R. Bootzin, Editors. 1985, Academic Press: San Diego, CA. p. 107-122.
- Lejuez CW, Paulson A, Daughters SB, Bornovalova MA, Zvolensky MJ. The association between heroin use and anxiety sensitivity among inner-city individuals in residential drug use treatment. Behav Res Ther. 2006 May;44(5):667-77. doi: 10.1016/j.brat.2005.04.006. Epub 2005 Jul 5.
- Lejuez CW, Zvolensky MJ, Daughters SB, Bornovalova MA, Paulson A, Tull MT, Ettinger K, Otto MW. Anxiety sensitivity: a unique predictor of dropout among inner-city heroin and crack/cocaine users in residential substance use treatment. Behav Res Ther. 2008 Jul;46(7):811-8. doi: 10.1016/j.brat.2008.03.010. Epub 2008 Mar 28.
- Schmidt NB, Norr AM, Allan NP, Raines AM, Capron DW. A randomized clinical trial targeting anxiety sensitivity for patients with suicidal ideation. J Consult Clin Psychol. 2017 Jun;85(6):596-610. doi: 10.1037/ccp0000195. Epub 2017 Mar 13.
- Barlow, D.H., et al., Behavioral treatment of panic disorder. Behavior Therapy, 1989. 20(2): p. 261-282.
Fechas de registro del estudio
Estas fechas rastrean el progreso del registro del estudio y los envíos de resultados resumidos a ClinicalTrials.gov. Los registros del estudio y los resultados informados son revisados por la Biblioteca Nacional de Medicina (NLM) para asegurarse de que cumplan con los estándares de control de calidad específicos antes de publicarlos en el sitio web público.
Fechas importantes del estudio
Inicio del estudio (Actual)
28 de mayo de 2019
Finalización primaria (Actual)
10 de enero de 2020
Finalización del estudio (Actual)
31 de enero de 2020
Fechas de registro del estudio
Enviado por primera vez
6 de mayo de 2019
Primero enviado que cumplió con los criterios de control de calidad
7 de mayo de 2019
Publicado por primera vez (Actual)
10 de mayo de 2019
Actualizaciones de registros de estudio
Última actualización publicada (Actual)
5 de noviembre de 2020
Última actualización enviada que cumplió con los criterios de control de calidad
3 de noviembre de 2020
Última verificación
1 de noviembre de 2020
Más información
Términos relacionados con este estudio
Términos MeSH relevantes adicionales
Otros números de identificación del estudio
- 365
Plan de datos de participantes individuales (IPD)
¿Planea compartir datos de participantes individuales (IPD)?
NO
Descripción del plan IPD
Data sets underlying this project will not be shared outside the VA, except as required under the Freedom of Information Act (FOIA), for a number of reasons.
First, data will be used by the research team to answer additional research questions.
Further, veterans may be hesitant to participate in research in which the data will be shared outside the VA and this may act as a barrier to participation and/or benefit from treatment.
Información sobre medicamentos y dispositivos, documentos del estudio
Estudia un producto farmacéutico regulado por la FDA de EE. UU.
No
Estudia un producto de dispositivo regulado por la FDA de EE. UU.
No
Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .